Cancer Research and Treatment

Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treatment Strategy for Metastatic Disease

Daniel V.T. Catenacci, Stephanie Moya, Samantha Lomnicki, Leah M. Chase, Bryan F. Peterson, Natalie Reizine, Lindsay Alpert, Namrata Setia, Shu-Yuan Xiao, John Hart, Uzma D. Siddiqui, D. Kyle Hogarth, Oliver S. Eng, Kiran Turaga, Kevin Roggin, Mitchell C.

Inhibiting casein kinase 2 overcomes paclitaxel resistance in gastric cancer

Minkyu Jung, Kyu Hyun Park, Hyun Myong Kim, Tae Soo Kim, Xianglan Zhang, Sun-Mi Park, Seung-Hoon Beom, Hyo Song Kim, Jae-Ho Cheong, Hyun Cheol Chung, John Soong, Shu-chuan Lin, Sun Young Rha

Advanced gastric cancer: is there an optimal chemotherapy regimen?

Kalliopi Andrikou, Massimiliano Salati, Annalisa Fontana, Andrea Spallanzani, Stefania Pipitone, Fabio Gelsomino, Monica Barbolini, Stefano Cascinu

Expert Review of Quality of Life in Cancer Care.2017; 2(2): 123. CrossRef

Third-line chemotherapy in advanced gastric cancer

Melatonin pre-treatment mitigates SHSY-5Y cells against oxaliplatin induced mitochondrial stress and apoptotic cell death

Mohammad Waseem, Upasana Sahu, Mohd. Salman, Arnab Choudhury, Sudeshna Kar, Heena Tabassum, Suhel Parvez, Saeid Ghavami

Outcomes of Advanced Gastric Cancer Patients Treated with at Least Three Lines of Systemic Chemotherapy

Valentina Fanotto, Mario Uccello, Irene Pecora, Lorenza Rimassa, Francesco Leone, Gerardo Rosati, Daniele Santini, Riccardo Giampieri, Samantha Di Donato, Gianluca Tomasello, Nicola Silvestris, Filippo Pietrantonio, Francesca Battaglin, Antonio Avallone,

Therapeutic effect of apatinib on overall survival is mediated by prolonged progression-free survival in advanced gastric cancer patients

Lihong Huang, Yongyue Wei, Sipeng Shen, Qianwen Shi, Jianling Bai, Jin Li, Shukui Qin, Hao Yu, Feng Chen

Giandomenico Roviello, Andrea Ravelli, Anna Ida Fiaschi, Maria Rosa Cappelletti, Angela Gobbi, Chiara Senti, Laura Zanotti, Karol Polom, Andrew R. Reynolds, Stephen B. Fox, Daniele Generali

Expert Review of Gastroenterology & Hepatology.2016; : 1. CrossRef

Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction

Jin Li, Shukui Qin, Jianming Xu, Jianping Xiong, Changping Wu, Yuxian Bai, Wei Liu, Jiandong Tong, Yunpeng Liu, Ruihua Xu, Zhehai Wang, Qiong Wang, Xuenong Ouyang, Yan Yang, Yi Ba, Jun Liang, Xiaoyan Lin, Deyun Luo, Rongsheng Zheng, Xin Wang, Guoping Sun,

Journal of Clinical Oncology.2016; 34(13): 1448. CrossRef

Efficacy and Safety of FOLFIRI as Second-line Chemotherapy in Advanced Gastric Cancer

The Korean Journal of Gastroenterology.2015; 66(1): 1. CrossRef

Efficacy and Safety of FOLFIRI after Failure of FOLFOX-4 in Advanced Gastric Cancer

Hye Jung Kwon, Moo In Park, Seun Ja Park, Won Moon, Sung Eun Kim, Hae Won Lee, Youn Jung Choi, Jae Hyun Kim

The Korean Journal of Gastroenterology.2015; 66(1): 10. CrossRef

Strategies and Advancements in Harnessing the Immune System for Gastric Cancer Immunotherapy

Vinod Vijay Subhash, Mei Shi Yeo, Woei Loon Tan, Wei Peng Yong

Journal of Immunology Research.2015; 2015: 1. CrossRef

Impact of the availability of active cytotoxic agents on the survival of patients with advanced gastric cancer

BYUNG HA CHO, HYE SOOK HAN, JIHYUN KWON, JOUNG-HO HAN, SOON MAN YOON, DAE HOON KIM, HYO YUNG YUN, KI HYEONG LEE, SEI JIN YOUN, SEUNG TAIK KIM

Design of precise third-line therapy for gastric cancer: target or chemotherpy?

The Korean Journal of Internal Medicine.2013; 28(3): 297. CrossRef

Sequential Chemotherapies for Advanced Gastric Cancer: A Retrospective Analysis of 111 Patients

Christoph Elsing, Christina Herrmann, Carla Verena Hannig, Wolfgang Stremmel, Dirk Jäger, Thomas Herrmann